Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results

Bibliographic Details
Main Author: Melo, Miguel
Publication Date: 2021
Other Authors: Gavina, Cristina, Silva-Nunes, José, Andrade, Luís, Carvalho, Davide
Format: Other
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/124269
Summary: Funding Information: MM participated in advisory board meetings and received speaker’s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting/speaker’s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly. Publisher Copyright: © 2021, The Author(s).
id RCAP_f749b70f7c89b9e91da129e035ead305
oai_identifier_str oai:run.unl.pt:10362/124269
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Heterogeneity amongst GLP-1 RA cardiovascular outcome trials resultscan definition of established cardiovascular disease be the missing link?Antidiabetic drugCardiovascular diseaseCardiovascular outcome trialsGLP-1 RAType 2 diabetesInternal MedicineEndocrinology, Diabetes and MetabolismSDG 3 - Good Health and Well-beingFunding Information: MM participated in advisory board meetings and received speaker’s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting/speaker’s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly. Publisher Copyright: © 2021, The Author(s).Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce blood glucose levels with a low associated risk of hypoglycaemia. CVOTs with different GLP-1 RAs yielded different results in terms of major cardiovascular composite outcome (MACE), with some trials showing superiority in the treatment arm, whereas other simply displayed non-inferiority. More importantly, the significance of each component of MACE varied between drugs. This begs the question of whether these differences are due to dissimilarities between drugs or other factors, namely trial design, are at the root of these differences. We analyse the trial designs for all CVOTs with GLP-1 RAs and highlight important differences between them, namely in terms of definition of established cardiovascular disease, and discuss how these differences might explain the disparate results of the trials and preclude direct comparisons between them. We conclude that a fair comparison between GLP-1 RA CVOTs would involve post-hoc analysis re-grouping the patients into different cardiovascular risk categories based upon their baseline clinical parameters, in order to even out the criteria used to classify patients.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNMelo, MiguelGavina, CristinaSilva-Nunes, JoséAndrade, LuísCarvalho, Davide2021-09-09T00:27:39Z2021-07-272021-07-27T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttp://hdl.handle.net/10362/124269engPURE: 33428612https://doi.org/10.1186/s13098-021-00698-5info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T17:55:58Zoai:run.unl.pt:10362/124269Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:26:55.236108Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
can definition of established cardiovascular disease be the missing link?
title Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
spellingShingle Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
Melo, Miguel
Antidiabetic drug
Cardiovascular disease
Cardiovascular outcome trials
GLP-1 RA
Type 2 diabetes
Internal Medicine
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
title_short Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
title_full Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
title_fullStr Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
title_full_unstemmed Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
title_sort Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
author Melo, Miguel
author_facet Melo, Miguel
Gavina, Cristina
Silva-Nunes, José
Andrade, Luís
Carvalho, Davide
author_role author
author2 Gavina, Cristina
Silva-Nunes, José
Andrade, Luís
Carvalho, Davide
author2_role author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Melo, Miguel
Gavina, Cristina
Silva-Nunes, José
Andrade, Luís
Carvalho, Davide
dc.subject.por.fl_str_mv Antidiabetic drug
Cardiovascular disease
Cardiovascular outcome trials
GLP-1 RA
Type 2 diabetes
Internal Medicine
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
topic Antidiabetic drug
Cardiovascular disease
Cardiovascular outcome trials
GLP-1 RA
Type 2 diabetes
Internal Medicine
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
description Funding Information: MM participated in advisory board meetings and received speaker’s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting/speaker’s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly. Publisher Copyright: © 2021, The Author(s).
publishDate 2021
dc.date.none.fl_str_mv 2021-09-09T00:27:39Z
2021-07-27
2021-07-27T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/124269
url http://hdl.handle.net/10362/124269
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv PURE: 33428612
https://doi.org/10.1186/s13098-021-00698-5
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596704131121152

Similar Items